APP Pharmaceuticals says it is prepared to meet all U.S. demand for multidose vials of therapeutic heparin after production difficulties for Baxter's competing product sparked concerns of drug shortages and led to intense congressional scrutiny of the FDA, including a call for the resignation of Commissioner Andrew von Eschen-bach.
展开▼